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Abstract
Background: A new 5-tiered grading grouping system has recently been endorsed for reporting of prostate cancer
(PCa) grade to better reflect escalating risk of progression and cancer death. While several validations of the new
grade groupings have been undertaken, most have involved centralised pathological
review by specialist urological pathologists.
Methods: Participants included 4268 men with non-metastatic PCa diagnosed between 2006 and 2013 from the
multi-institutional South Australia Prostate Cancer Clinical Outcomes Collaborative registry. PCa-specific survival and
biochemical recurrence-free survival were compared across the five grade groups using multivariable competing
risk regression.
Results: For the entire cohort, risk of PCa death increased with increasing grade groups (at biopsy) Adjusted
subdistribution-hazard ratios [sHR] and 95% confidence intervals [95%CI] were: 2.2 (1.5–3.6); 2.5 (1.6–4.2); 4.1 (2.6–6.7)
and 8.7 (4.5–14.0) for grade groups II (pattern 3 + 4), III (pattern 4 + 3), IV (total score 8) and V (total score 9–10)
respectively, relative to grade group I (total score < =6). Clear gradients in risk of PCa death were observed for
radical prostatectomy (RP), but were less clear for those who had radiotherapy (RT) with curative intent and those
who were managed conservatively. Likewise, risk of biochemical recurrence increased across grade groups, with
a strong and clear gradient for men undergoing RP [sHR (95%CI): 2.0 (1.4–2.8); 3.8 (2.9–5.9); 5.3 (3.5–8.0); 11.2
(6.5–19.2) for grade groups II, III, IV and V respectively, relative to grade group I], and a less clear gradient for
men undergoing RT.
Conclusion: In general, the new five-tiered grade groupings distinguished PCa survival and recurrence outcomes
for men with PCa. The absence of a clear gradient for RT may be due to heterogeneity in this patient group.
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Background
Histological grade is an important prognostic indicator for
prostate cancer (PCa) and is used extensively in defining
risk categories for disease progression, along with other
clinical characteristics, to guide treatment decisions and
follow-up care [1–3]. The Gleason grading system devel-
oped 50 years ago, has been the universally adopted
grading system for PCa, and has undergone a number of
modifications. Major changes introduced in 2005 [4] led
to significant upward shift in grade assignment from that
time [5, 6].
Since then, a new more ‘patient friendly’ system for
categorising prostate cancer grade, originally proposed
by Epstein [7], has been endorsed by the International
Society of Urological Pathologists (ISUP) [8]. The new
grading system proposes reporting grade according to 5
risk groups reflecting an escalating risk of progression
and cancer death, namely grade group I (Gleason
≤3 + 3 = 6), grade group II (Gleason 3 + 4 = 7); grade
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group III (Gleason 4 + 3 = 7); grade group IV (total
Gleason score = 8); and grade group V (total Gleason
Score = 9–10). Separating total Gleason score of 7 into
patterns 3 + 4 and 4 + 3 provides official recognition of
the prognostic differences between these designations
[7, 9–12], differences which have long been recognised
and considered by clinicians in determining treatment
options. A further distinction has been made between
total Gleason scores 8 and 9–10, which are generally
grouped together as a single high risk category in most
risk classification systems.
One of the key motivations for reclassifying grade into
these five new groups is to better convey to a non-clinical
audience the level of risk associated with disease grade.
Labelling the lowest grade category as grade group I ra-
ther than Gleason Score of 6, provides a greater sense of
lower risk of disease progression, and may help some men
accept a recommendation for active surveillance rather
than definitive treatment in the first instance.
Several validation studies have confirmed the predict-
ive accuracy of the new grade groupings for biochemical
recurrence (BCR) in international cohorts, both for men
undergoing radical prostatectomy (RP) [7, 13–15] and
radiotherapy treatment (RT) [13, 16, 17]. The new grade
groupings have also been validated with respect to risk
of prostate cancer death [18]. These include two recently
published Australian validation studies which examined
the performance of the new five-tier grade groupings in
both men undergoing RP [15] and men undergoing RT
in a trial setting [17]. All of these studies included centra-
lised assessment or review of biopsy specimens. In the
community setting multiple pathology services are en-
gaged in assessing grade at biopsy and on RP specimens,
and not all cases undergo specialist uro-pathological re-
view. Consequently grade reported to clinicians and pa-
tients is not standardised and may not be uniform. Hence,
it is also important to examine the applicability of the
proposed new grading groupings in the context of non-
centralised grading in a community based setting.
To this end, the aim of this study was to examine
oncological outcomes, i.e. risk of PCa mortality and
biochemical recurrence [BCR], according to new five-tier
grade groupings for different management approaches,
within a multi-institutional, community-based cohort
from Australia.
Methods
Data source and subjects
The South Australian Prostate Cancer Clinical Outcomes
Collaborative (SA-PCCOC) database is a long running
prospective clinical registry which collects tumour charac-
teristics, treatment details and oncological and functional
outcome data for men with PCa across both the public
and private sector in South Australia [19]. The study
sample included all men in the SA-PCCOC registry
with localised PCa diagnosis between 2006 and 2013
who had biopsy Gleason grade patterns recorded.
During this period, registry coverage was approximately
50% of all cases in the state and included recruitment
from all public hospitals, which are government run
with universal access for all Australians, as well as ap-
proximately 50% of private urologists/urology services.
Diagnoses before 2006 were excluded to limit cases to
those graded after ISUPs revision of the grading system
in 2005. Men with evidence of metastatic disease (clinical
or imaging) at or within 45 days of diagnosis were also
excluded, since metastatic disease may distort outcome
assessment by grade.
Measures
Data on patient characteristics including age at diagnosis,
public or private health care management, place of resi-
dence; clinical features including grade, prostate specific
antigen [PSA] levels, stage, and symptomatic presentation
(i.e. referral due to symptoms - i.e. lower urinary tract
symptoms, haematuria, bone pain – versus referral for
elevated PSA), primary and subsequent treatment modal-
ities, and dates of biochemical recurrence and death were
extracted from SA-PCCOC for eligible cases. An area level
measure of socioeconomic status was derived from
patient’s residential postcode, using the Australian Bureau
of Statistics Index of Socioeconomic Advantage and
Disadvantage [20]. Death data were obtained from both
the South Australian Register of Births, Deaths, and
Marriages and the National Death Index.
For analyses of outcomes among men receiving curative
treatment, we restricted the cohort to men who received
curative RP or RT within 12 months of diagnosis. RT
included external beam radiotherapy (EBRT), brachyther-
apy, or a combination of both. Conservative management
was defined as management via watchful waiting (WW),
active surveillance (AS) or androgen deprivation therapy
(ADT) alone.
Grade at diagnosis, grouped according to the recently
endorsed five-tiered system [8], was the key variable of
interest in this study. For comparative purposes only
biopsy grade was considered across all treatment groups
including radical prostatectomy. Key outcomes in this
study were prostate cancer-specific survival (PCSS) and
biochemical recurrence-free survival (BRFS). PCSS was
defined as the time from diagnosis to death, where PCa
was indicated on the death certificate as a primary con-
tributing cause of death. BRFS was defined as the time
from date of diagnosis to first evidence of biochemical
recurrence (BCR) among men who underwent definitive
treatment. BCR was defined for patients receiving RP as
two consecutive PSA values of >0.2 ng/mL [21], and for
those receiving primary radiation therapy, any PSA
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increase >2 ng/mL higher than the post-RT PSA nadir
value, regardless of the serum concentration of the nadir
[22]. Survival durations were calculated from the date of
diagnosis until the date of BCR, death or censoring date
of June 30, 2016 (i.e. most recent deaths/PSA update),
which ever was earliest.
Analysis
Descriptive analyses of demographic, clinical and treat-
ment characteristics according to grade groups were
undertaken, with extended Wilcoxon rank-sum tests used
to assess trends across ordered groups. Survival outcomes
were initially assessed using Kaplan-Meier methods with
log rank tests for differences in survival by grade groups.
For Kaplan-Meier curves and log rank analyses competing
risks are censored.
PCSS and BRFS were also compared across biopsy
grade groupings (I to V) using univariable and multivari-
able competing risk regression, according to Fine and
Gray’s methodology [23], with death from causes other
than PCa as the competing risk. We undertook analyses
for the entire cohort as well as for separate treatment
subgroups: conservative management, RP and curative
RT. All regression models controlled for age at diagnosis
(continuous), year of diagnosis (continuous), public or
private healthcare management, closest preceding PSA
level to diagnosis (<10, 10- < 20, 20 + ng/ml), clinical
stage (<cT3 v cT3+), symptomatic presentation (yes/no),
and where appropriate, specific treatment types (e.g.
robot-assisted versus open surgery, brachytherapy ver-
sus EBRT, ADT) and total dose received in Grays (con-
tinuous) for RT patients. Wald’s test was used to test
for significant trends across grade groups in multivari-
able models. The potential for pairwise interactions
between grade and other baseline factors was explored
using likelihood ratio tests, comparing nested models
with and without interactions. Statistically significant
interactions were observed for treatment approaches
and grade, in relation to both PCa mortality (p = 0.03),
and BCR (p < 0.001). We therefore report results of
subgroup analyses for different treatment modalities.
Due to known inaccuracies in assessing grade at biopsy,
a sensitivity analyses was also undertaken for the subset
who underwent RP, comparing the discriminatory power
of prostatectomy versus biopsy grade to predict biochem-
ical recurrence via the Akaike Information Criteria (AIC)
in separate multivariable models.




Data were available for a total of 4268 men, diagnosed
between 2006 and 2013. Two thirds of patients were
classified as grade group I or II on biopsy, according to
the new grade groupings. The mean age at diagnosis
increased with increasing grade, as did median PSA at
diagnosis (see Table 1). The proportion of men present-
ing with symptoms at diagnosis also increased with
increasing grade groupings. However, grade groups did
not differ with respect to number of cores taken at
biopsy (median = 12). In the case of grade group V, a
higher proportion was managed in the public system
compared with other grade groups.
As expected, treatment patterns varied considerably
across grade groups. RP was the primary treatment in
40% of men with grade group I and 51% with grade
group II, but only 14% for men with grade group V
disease. RT as the primary treatment was less variable.
The proportion receiving RT with curative intent ranged
from 27% for grade group I to 38% for grade group III
and 39% for grade group V. Twenty seven percent of
men in grade group I and 10% in grade group II under-
went observation without immediate treatment.
Five-year PCSS decreased from 98% (95% CI 97–99%)
for grade group I to 64% (95% CI 59–69%) for grade
group V. Five-year BRFS decreased from 91% (95% CI
89–93) among men in grade group I to 67% (95% CI
57–75) for grade group V. The median follow-up time
for the whole cohort was 72 months (inter-quartile
range 52–96 months).
Prostate cancer specific survival
Figure 1 presents Kaplan-Meier PCa-specific survival
curves for each of the new five-tier grade groupings I –
V for the whole cohort. Survival decreased incrementally
with higher grade grouping, as expected. Table 2 pre-
sents results of unadjusted and covariate adjusted com-
peting risk regressions for PCa mortality across grade
groups. Adjustment for covariates attenuated the effect
of grade on risk of PCa death, in some instances quite
considerably. This is likely to be explained by associa-
tions with other prognostic factors (age and PSA levels)
across grade groups. Using backwards elimination model-
ling we confirmed that differences in age and pre-treatment
PSA levels were the main factors contributing to the at-
tenuation effect. Even so, grade remained the strongest in-
dependent predictor of death from PCa.
Within the entire cohort, risk of PCa death increased
incrementally with increasing grade group, independ-
ently of other factors, based on multivariable competing
risk regression (adjusted sub-distribution hazard ratios
[sHR] = 2.2 (1.5–3.6); 2.5 (1.6–4.2); 4.1 (2.6–6.7) and 8.7
(4.5–14.0) for grade groups II, III, IV and V respectively,
relative to grade group I. A similar gradient in risk of PC
death was observed among men who - who underwent
RP. For men managed conservatively and men who re-
ceived curative RT, a clear increase in SHRs across grade
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groups was not evident, however p-values for trend were
statistically significant in all treatment subgroups.
Biochemical recurrence-free survival
Figure 2 presents survival curves for BCR by grade
groups for patients treated curatively, indicating poorer
outcomes with increasing grade group. Results from
competing risk regression analyses for BCR by grade
groups are shown in Table 3. These analyses show a
clear gradient in risk of BCR across grades following RP
(p for trend < 0.001). For patients who received curative
RT, we did not observe a constant increase in sHRs
across grade groups, though the trend overall was statis-
tically significant (<0.001). Including type of RT (EBRT
versus brachytherapy), total dose and concurrent or
adjuvant ADT in the model did not alter this pattern.
Likewise, findings did not change when men receiving
neo-adjuvant or adjuvant ADT were excluded.
Incremental comparison between grade groups
To specifically compare outcomes between incremental
grade groups we repeated multivariable competing risk
regression models with each grade group referenced to
the previous grade grouping (Table 4). With respect to
PCa death we observed non-significant trends toward
higher risk for Grade group III compared with II among
men undergoing radical prostatectomy (sHR = 1.4, CI
0.3-6.5) and men receiving curative radiotherapy
(sHR = 1.6, CI 0.9–3.1). The lack of statistical signifi-
cance is likely to be due to the low number of PCa
deaths among men in these grade groupings. With re-
spect to BCR, comparisons showed statistically signifi-
cant higher risk of progression for grade group III
compared with grade group II for both treatment groups
(RP: sHR = 2.1, CI 1.5–2.8; RT: sHR = 2.0, CI 1.3–3.1).
Comparisons of grade groups IV and grade group III in-
dicated statistically significant differences for risk of PCa
death for men undergoing RP (sHR = 4.2, CI 1.0–17.1)
and men managed conservatively (sHR = 1.9, CI 1.0–
3.4) but not for men undergoing curative RT, and no dif-
ference in relation to risk of BCR for either curative ap-
proach. Risk of PCa death and BCR were both elevated
for men in grade group V compared with IV for RP and
RT patients, but the difference only reached statistical
significance in relation to BCR for men undergoing RP.
Among men who were managed conservatively we ob-
served a significant difference in risk of PCa death for
grade group V compared grade group IV (sHR = 2.1, CI
1.3–3.4), but saw no difference in risk death between
grade groups II and III).
Table 1 Cohort characteristics by the new 5 tier Grade Groups (at biopsy)
Grade Groups
Characteristics (N = 4268) I II III IV V p-valuea
Total - n (%) 1782 (42) 1154 (27) 647 (15) 399 (9) 286 (7)
Clinical characteristics
Mean age - years (SD) 66 (9) 67 (9) 70 (10) 72 (9) 74 (10) <0.001
Median PSA - ng/mL (IQR) 7 (5–10) 8 (6–12) 10 (7–16) 11 (7–20) 17 (8–20) <0.001
Public patient - no. (%) 952 (53) 594 (51) 316 (49) 223 (56) 190 (66) <0.001
Presented with symptoms - no. (%) 395 (22) 229 (20) 112 (17) 80 (20) 87 (30) <0.001
Primary Treatment - n (%)
Radical Prostatectomyb 719 (40) 592 (51) 260 (40) 130 (33) 39 (14) <0.001
Radiotherapyb,c (with curative intent) 488 (27) 356 (31) 243 (38) 136 (34) 111 (38) <0.001
Observation (AS or WW) 488 (27) 109 (9) 75 (12) 48 (12) 49 (17) <0.001
ADT alone 31 (2) 54 (5) 47 (7) 62 (15) 71 (25) <0.001
Outcomes
PCa deathsd – no. (%) 40 (2) 52 (5) 42 (7) 48 (12) 77 (27) <0.001
Other deathsd – no. (%) 157 (9) 115 (10) 75 (12) 61 (15) 34 (12) <0.001
Biochemical recurrenced – no. (%) 104 (11) 136 (17) 124 (29) 70 (30) 44 (37) <0.001
PCa survival (5 yrs) - % (95% CI) 98 (97–99) 96 (95–97) 95 (93–96) 84 (80–88) 64 (59–69) <0.001
BCR free survival (5 yrs)e - % (95% CI) 91 (89–93) 84 (81–86) 73 (68–77) 70 (63–76) 67 (57–75) <0.001
Corresponding Gleason patterns/scores for grade groups I-V are: 3 + 3, 3 + 4, 4 + 3, 8, 9–10
aP-values from: log rank tests for survival & nonparametric tests for trend across ordered groups
bIncludes RP/ curative RT at any time after diagnosis
cRT includes external beam, brachytherapy, or combination of both
dTotal number of events during the follow-up period
eBiochemical recurrence among men who received definitive treatment (with PSA follow-up data) n = 2770
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Sensitivity analyses
Comparison of biopsy and prostatectomy grade groups
among men who underwent radical prostatectomy indi-
cated that prostatectomy grade was marginally superior to
biopsy grade in predicting BCR following RP, as indicated
by the difference in AIC for the two models (Table 5).
Discussion
The new 5-tiered grade groups (determined at biopsy)
correlated well with increasing risk of PCa mortality and
risk of disease progression in most instances. Although
adjustment for other prognostic factors attenuated differ-
ences across grade groups, grade was a strong predictor of
disease specific outcomes in our cohort. In general, these
findings indicate the generalizability of findings from val-
idation studies with standardised pathology undertaken by
specialist urological pathologists [7, 13, 17, 25] to commu-
nity practice with non-centralised pathology undertaken
predominantly by non-specialist pathologists. Even so,
there is room for improvement in diagnostic methods,
given that grade assessed on radical prostatectomy speci-
mens better discriminated of the risk of BCR than grade
assessed at biopsy.
Our study confirms the widely reported findings by
others [7, 10–12] which indicate that grade groups II
and III (which previously were often grouped together as
a total Gleason score = 7) confer different levels of risk
of BCR among men undergoing RP or RT. Our results
also support making a distinction between a total
Gleason score of 8 (grade group IV) and scores of 9 and
10 (grade group V) [26, 27], since risk of BCR is higher
for grade group V compared with IV for both treatment
subgroups. Among men managed conservatively, statisti-
cally significant differences were observed between grade
groups IV and V, but not between grade groups II and
III. The lack of distinct difference may be due to the very
mixed nature of the cohort being managed conserva-
tively. An examination of the differences in outcomes
between patterns (3 + 5 vs 4 + 4 vs 5 + 3) within grade
group IV, which remains controversial [28, 29], was be-
yond the scope of this paper.
A clear gradient of worsening outcomes was observed
with increasing grade group among men receiving RP,
but was less prominent for men undergoing curative RT.
Risk of BCR among men undergoing curative RT was
effectively identical for grade III to V, contrary to expec-
tations. This irregularity was not explained by differences
in RT dose or treatment type. Results remained similar
when models included receipt of concurrent/adjuvant
ADT and also when those who received adjuvant therapy
were excluded. Interestingly, others reporting outcomes
across grade groups among men undergoing RT have also
Fig. 1 Unadjusted Kaplan-Meier survival curves for prostate cancer specific mortality, by grade groups at biopsy. [Grade I = (3 + 3); Grade II = (3 + 4);
Grade III = (4 + 3); Grade IV = (total score = 8); Gleason 5 = (total score = 9–10)]
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not shown a clear gradient, similar to our results [13,
16, 17]. Possible reasons for the lack of a clear gradient
in outcomes among RT patients include: 1) the influ-
ence of other unmeasured confounders, given the
mixed characteristics within the subgroup receiving RT,
e.g. those with higher risk disease as well as those with
lower risk disease who were not fit for surgery; 2) in-
correct assignment of grade at biopsy with potentially
higher levels of misclassification, since RT patients
tended to be older and have higher PSA levels which
are both associated with upgrading [30]), or 3) different
effects of RT for different grade groups, that is, RT may
be more effective for higher and less effective for lower
grade tumours leading to less distinct survival curves.
Among men managed conservatively, there was a clear
difference in risk of PCa mortality between grade groups
I and II. This result provides some support for AS
among men whose tumour are classified as grade group
I, provided other prognostic indicators are favourable.
Conversely, a case could be made for actively treating
men with grade II disease if they are fit for surgery, since
prostate cancer survival among those who were man-
aged conservatively was significantly worse for grade
group II compared with I. Currently, some guidelines
recommend offering AS for favourable intermediate risk
(grade group II) disease, determined largely by the ex-
tent of Gleason pattern 4 [31, 32]. Our data do not offer
this level of granularity. Furthermore, interpretation of
Table 2 Risk of prostate cancer death by the new 5-tier grade groups within treatment subgroups









Grade group I (3 + 3) 40/1780 1.0 - 1.00
Grade group II (3 + 4) 52/1154 2.1 (1.4–3.2) <0.001 2.2 (1.5–3.6) <0.001
Grade group III (4 + 3) 42/645 3.2 (2.1–4.9) <0.001 2.5 (1.6–4.2) <0.001
Grade group IV (8) 48/399 6.1 (4.0–9.2) <0.001 4.1 (2.6–6.7) <0.001
Grade group V (9–10) 77/286 16.8 (11.4–24.7) <0.001 8.7 (5.4–14.0) <0.001
P for trend <0.001 <0.001
Conservative managementb 136/1033
Grade group I (3 + 3) 19/518 1.0 - 1.00
Grade group II (3 + 4) 25/163 4.3 (2.4–7.8) <0.001 3.0 (1.5–5.8) 0.001
Grade group III (4 + 3) 17/122 3.9 (2.1–7.4) <0.001 2.2 (1.0–4.8) 0.04
Grade group IV (8) 26/110 6.9 (3.8–12.4) <0.001 4.1 (2.0–8.4) <0.001
Grade group V (9–10) 49/120 15.2 (8.9–25.8) <0.001 8.5 (4.2–17.2) <0.001
P for trend <0.001 <0.001
Radical prostatectomy 22/1624
Grade group I (3 + 3) 4/637 1.0 - 1.0 -
Grade group II (3 + 4) 5/568 1.7 (0.5–6.2) 0.44 1.6 (0.4–6.1) 0.48
Grade group III (4 + 3) 3/254 2.4 (0.5–10.5) 0.26 2.3 (0.5–10.9) 0.29
Grade group IV (8) 6/126 9.5 (2.6–33.8) 0.001 9.5 (2.6–35.8) 0.001
Grade group V (9–10) 4/39 29.1 (7.1–120) <0.001 28.4 (6.4–124) <0.001
P for trend <0.001 <0.001
Curative radiotherapy 75/1143
Grade group I (3 + 3) 15/385 1.0 - 1.00 -
Grade group II (3 + 4) 19/314 1.8 (0.9–3.5) 0.10 1.4 (0.7–3.0) 0.37
Grade group III (4 + 3) 19/218 2.7 (1.4–5.5) 0.003 2.3 (1.1–4.8) 0.03
Grade group IV (8) 10/125 2.6 (1.2–5.8) 0.02 2.0 (0.8–7.8) 0.13
Grade group V (9–10) 12/101 4.2 (2.0–9.0) <0.001 2.8 (1.2–6.8) 0.02
P for trend <0.001 <0.001
asHR: Sub-distribution hazard ratios derived from competing risk regression adjusted for age, year of diagnosis, diagnostic PSA, clinical stage, area level SES, public
/private management, treatment modality (appropriate to subgroups)
bThe conservative management group consists of men who were managed through watchful waiting, active surveillance or androgen deprivation therapy alone
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Fig. 2 Unadjusted Kaplan-Meier survival curves for biochemical recurrence-free survival, by grade groups at biopsy. [Grade I = (3 + 3); Grade I
I = (3 + 4); Grade III = (4 + 3); Grade IV = (total score = 8); Gleason 5 = (total score = 9–10)]
Table 3 Risk of biochemical recurrence (BCR) by the new five-tier grade groupings among men having definitive treatment









Clinical grade groups N = 1351
Grade group I (3 + 3) 57/541 1.0 - 1.0 -
Grade group II (3 + 4) 94/468 2.0 (1.5–2.9) <0.001 2.0 (1.4–2.8) <0.001
Grade group III (4 + 3) 73/200 4.1 (2.9–5.9) <0.001 3.8 (2.9–5.9) <0.001
Grade group IV (8) 47/108 5.5 (3.7–8.0) <0.001 5.3 (3.5–8.0) <0.001
Grade group V (9–10) 21/34 9.5 (5.6–16.1) <0.001 11.2 (6.5–19.2) <0.001
P for trend <0.001 <0.001
Curative radiotherapy N = 937 185/937
Grade group I (3 + 3) 46/321 1.0 - 1.0 -
Grade group II (3 + 4) 42/254 1.2 (0.8–19) 0.291 1.2 (0.7–1.8) 0.32
Grade group III (4 + 3) 51/187 2.4 (1.8–3.6) <0.001 2.5 (1.5–3.7) <0.001
Grade group IV (8) 23/97 2.0 (1.2–3.4) 0.006 2.0 (0.9–2.9) 0.02
Grade group V (9–10) 23/78 2.4 (1.8–5.2) <0.001 2.4 (1.4–4.1) 0.001
P for trend <0.001 <0.001
Cases were excluded if <2 post- treatment PSA measures were recorded (273 (17%) cases excluded for prostatectomy group; 206 (18%) cases excluded for
radiotherapy subgroup)
asHR: Sub-distribution hazard ratios derived from competing risk regression adjusted for age, year of diagnosis, diagnostic PSA, clinical stage, area level SES, and
public/private management
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outcomes for the conservatively managed group is difficult
given this subgroup of patients includes a mix of lower
risk cases under active surveillance and older higher risk
patients undergoing watchful waiting and/or intermittent
hormone treatment. (Data on intent of conservative
management approaches were not available for the entire
study period, hence further subdivision was not possible).
This mix of patient characteristics may be contributing to
or masking differences across grade groups.
Finally further research is needed to develop new risk
stratification tools for disease progression/PCa mortality
based on new grade classifications in combination with
Table 4 Risk of prostate cancer (PCa) death and biochemical recurrence (BCR), relative to previous grade grouping, by biopsy grade
Treatment sub-group PCa deaths BCRa
Adjusted sHR (95%CI) p Adjusted sHRb (95%CI) p
Radical prostatectomy
Grade group I (3 + 3) - - -
Grade group II (3 + 4) 1.6 (0.4–6.1) 0.48 2.0 (1.4–2.8) <0.001
Grade group III (4 + 3) 1.4 (0.3–6.5) 0.64 2.1 (1.5–2.8) <0.001
Grade group IV (8) 4.2 (1.0–17.1) 0.05 1.4 (0.9–2.0) 0.12
Grade group V (9–10) 3.0 (0.8–10.9) 0.10 1.8 (1.0–3.1) 0.05
Curative radiotherapy
Grade group I (3 + 3) - -
Grade group II (3 + 4) 1.4 (0.7–3.0) 0.37 1.2 (0.7–1.8) 0.32
Grade group III (4 + 3) 1.6 (0.9–3.1) 0.13 2.0 (1.3–3.1) 0.001
Grade group IV (8) 0.9 (0.4–2.0) 0.74 0.8 (0.5–1.4) 0.41
Grade group V (9–10) 1.4 (0.6–3.5) 0.46 1.3 (0.7–2.4) 0.46
Conservative managementc
Grade group I (3 + 3) -
Grade group II (3 + 4) 3.0 (1.5–5.8) 0.001 Not applicable
Grade group III (4 + 3) 0.7 (0.4–1.4) 0.35 -
Grade group IV (8) 1.9 (1.0–3.4) 0.04 -
Grade group V (9–10) 2.1 (1.3–3.4) 0.004 -
aFor analysis of BCR, cases were excluded if <2 post- treatment PSA measures were recorded (273 (17%) cases excluded for prostatectomy group; 206 (18%) cases
excluded for radiotherapy subgroup)
bsHR: Subdistribution-hazard ratios derived from multivariable competing risk regression adjusted for age, year of diagnosis, diagnostic PSA, clinical stage, area
level SES, and public/private management
cThe conservative management group consists of men who were managed through watchful waiting, active surveillance or androgen deprivation therapy alone




Biopsy grade grouping Prostatectomy grade grouping
No. events/total Adjusted sHRa (95% CI) p-value No. events/total Adjusted sHRa (95% CI) p-value
292/1334 292/1334
Grade group I (3 + 3) 57/532 1.0 − 19/286 1.0 −
Grade group II (3 + 4) 94/462 2.0 (1.5–2.9) <0.001 87/595 2.4 (1.5–3.9) 0.001
Grade group III (4 + 3) 73/199 4.3 (3.0–6.2) <0.001 119/321 7.6 (4.6–12.4) <0.001
Grade group IV (8) 47/108 5.8 (3.9–8.7) <0.001 25/62 9.0 (4.8–17.0) <0.001
Grade group V (9–10) 1/34 10.4 (5.9–18.2) <0.001 42/70 16.8 (9.6–29.7) <0.001
P for trend <0.001 <0.001
AICb 3934 3882
Change in AIC +52 0
Models only include cases with detail on both biopsy and prostatectomy grade sufficient to determine ISUP-2014 groups and ≥2 post-treatment PSA measures
asHR: subdistribution Hazard ration from multivariable competing risk regression models adjusted for age, pre-treatment PSA, clinical evidence of extra prostatic
disease, symptomatic presentation, public or privately managed
bLower (AIC: Akaike’s Information Criterion) indicates better discriminatory power for prostatectomy grade compared with biopsy grade groups
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other clinical characteristics, e.g. diagnostic PSA levels,
to provide patients and clinicians with more refined
risk-based information to guide treatment decisions.
Limitations
In undertaking this study, we did not commission a review
of the original grade assignment but rather reclassified
groupings based on recorded primary and secondary
Gleason patterns. Nor did we include tertiary pattern 5 in
grade classification, as it was not always recorded.
Also, we were unable to account for potential con-
founding by factors such as comorbidity and frailty,
due to a lack of information on these measures. Co-
morbidity/frailty may be contributing to poorer clinical
outcomes for men in the lower grade groups, particu-
larly those undergoing radiotherapy or conservative
management due to being unfit for surgery. Not being
able to account for these factors may have obscured the
influence of grade, leading to less clear incremental ef-
fect across grade groups in these treatment subgroups.
This is supported by the smaller effect sizes for grade
among men receiving RT compared to those observe
for the RP subgroup.
Since state-wide coverage was only 50% and private
patients were likely underrepresented in SA-PCCOC
during the study period, our results may be affected by
selection bias. Given public patients are likely to be
older and have more comorbidities and, or more ad-
vanced disease, the likely impact of such bias would be
toward reduced strength of association between grade
groups and clinical outcomes. This may be another fac-
tor explaining the less clear distinction in men receiv-
ing RT or managed conservatively.
The strengths of this study in relation to assessing ap-
plicability of the new grading classification in a commu-
nity setting are a relatively long follow-up time and
multi-institutional nature of our cohort.
Conclusion
The newly proposed five-tier grade groupings distinguish
risk of disease progression and PCa mortality reasonably
accurately in our cohort, with the exception of some
anomalies in relation to disease progression following
RT and for men managed conservatively. This may be
due to heterogeneity with respect to other factors within
these groups. In general our findings indicate the applic-
ability of the new grade group, assigned in the context
of non-standardised assessment of grade across multiple
practices in a community based setting.
These results lend support to the adoption of the new
grading classification, whereby men with low risk
(grade group I) disease may be encouraged to consider
surveillance in the first instance.
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